Influence Best Practice in Observational Research
– Get Involved in GRACE
We are seeking to build broad support for the GRACE Initiative and to develop refinements and specialized applications to the Checklist and Principles. We invite endorsement of the GRACE Principles from organizations, journals, and other groups.
Join the GRACE community to
- Discuss gold standards that could be used for validation
- Become a collaborator
- Volunteer to help test extended applications
If you are interested in contributing to or supporting the GRACE initiative, please fill out the form below to be contacted for future opportunities.
Fill out my online form.
Contributors, Collaborators and Supporters
Contributors have provided periodic consultation and advice
- Nancy Berkman, RTI International
- Nick Black, London School of Hygiene and Tropical Medicine
- Alan Brookhart, Associate Professor, Department of Epidemiology, University of North Carolina at Chapel Hill Gillings School of Global Public Health
- Sarah Garner, Research & Development, NICE
- Tobias Gerhard, Ernest Mario School of Pharmacy, Rutgers University
- Kathy Lohr, RTI International
- Newell McElwee, US Outcomes Research, Merck & Co., Inc.
- Barbara McNeil, Health Care Policy, Harvard Medical School
- Peter Neumann, Director, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center; Professor, Tufts University School of Medicine
- Dan Ollendorf, Institute for Clinical & Economic Review
- Steve Pearson, President, Institute for Clinical and Economic Review, Massachusetts General Hospital Institute for Technology Assessment
- Sebastian Schneeweiss, Harvard Medical School; Dept. of Medicine, Brigham & Women's Hospital
- Tarang Sharma, Research & Development, NICE
- Daniel Singer, Clinical Epidemiology, Harvard Medical School; Epidemiology, Outcomes, and Disease, Management Unit, MGH Clinical Research Program
- Harold C. Sox, Professor of Medicine (emeritus, active), Dartmouth Medical School; Associate Director for Faculty; The Dartmouth Institute for Health Policy and Clinical Practice
- Brian Sweet, Healthcare Alliances, AstraZeneca
- Sean Tunis, Center for Medical Technology Policy (CMTP)
- Meera Viswanathan, RTI International
- Noel Weiss, Professor of Epidemiology, School of Public Health, University of Washington
Testers have assisted with checklist validation
- Daniel Ankrah, Korle-Bu Teaching Hospital
- Quazi Ataher, Worldwide Safety Strategy, Pfizer
- Anjan Banerjee, PopeWoodhead & Associates; Institute of Biotechnology, Cambrdige University
- Henny Bang Jakobsen, Medical Sciences, Nycomed: a Takeda Company
- Kathleen Bennett, Department of Pharmacology and Therapeutics, Trinity Centre for Health Sciences, St. James Hospital
- Nirmala Bhoo Pathy, National Clinical Research Centre, Malaysia
- William Blumentals, Shionogi Inc.
- Rachael Boggon, Medicines and Healthcare Products Regulatory Agency, UK
- Denise Boudreau, Pharmacoepidemiology, Group Health Research Institute
- Suzanne Cadarette, Pharmacoepidemiology and Health Services Research, U. of Toronto
- Aisling R Caffrey, Veterans Affairs Medical Center, Providence, Rhode Island
- Tara Chang, Stanford School of Medicine
- Richard Chapell, Outcomes Research, Merck & Co., Inc.
- Yingkai Cheng, Global Patient Safety, Eli Lilly
- Moni Choudhury, Research & Development, NICE
- Preciosa Coloma, Medical Informatics, Erasmus Medical Center
- Nicole Cossrow, Worldwide Market Access, Johnson & Johnson
- Simon Crespi, Merck
- Concetta Crivera, Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC
- CV Damaraju, Biostatistics, Janssen R&D
- Cynthia de Luise, Worldwide Safety Strategy, Pfizer
- Jenny Devenport, Biostatistics, Genentech
- Andrew Eggleston, Reimbursement and Health Economics, Medtronic
- Eric Elkin, Late Phase & Outcomes Research (ILPOR), ICON
- Sherif Eltonsy, University of Montreal
- Efe Eworuke, Department of Pharmaceutical Outcomes and Policy, University of Florida
- Christine Fletcher, Amgen Ltd.
- Joy Frestedt, Clinical Research, Frestedt Incorporated
- Jon Fryzek, Exponent
- Christiane Gasse, National Centre for Register-based Research, Aarhus University, Denmark
- Yvonne Geissbühler, Global Epidemiology, Novartis Pharma AG
- Cynthia Girman, Epidemiology, Merck Research Laboratories
- Lisa Griffin-Vincent, Regulatory & Clinical Research Institute, Inc.
- Joanna Haas, Global Patient Safety and Risk Management, Genzyme
- Jamaiyah Haniff, Clinical Research Centre, Ministry of Health, Malaysia
- Daniel Hartung, Pharmacoeconomics, Oregon State University
- Jinghua He, Pharmacoepidemiology, Merck Research Laboratories
- Kim Heithoff, US Outcomes Research, Merck & Co., Inc.
- Allen H. Heller, Bayer HealthCare Pharmaceuticals
- Ken Hornbuckle, Global Patient Safety, Eli Lilly and Company
- Xing-Yue Huang, Health Economics and Outcomes Research, Forest Research Institute, Inc.
- Krista Huybrechts, Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School
- Mike Ingham, Health Economics & Outcomes Research, Janssen Biotech
- Ralph Insinga, Health Economics and Statistics, Merck Research Laboratories
- Jessica Jalbert, LA-SER Group
- Ani John, Immunology Registries, Genentech
- Juhaeri Juhaeiri, Pharmacoepidemiology, Sanofi-Aventis
- Marmar Kabir-Ahmadi, Epidemiology, Sanofi France
- Bindweep Kaur, Research & Development, NICE
- Xuehua Ke, WellPoint, Inc.
- John Hon Yoon Khee, National Clinical Research Centre, Malaysia
- Matthijs Killian, Cochlear Technological Center, Belgium
- Arun Krishna, Merck
- R.Scott Leslie, MedImpact Healthcare Systems, Inc
- Huifang Liang, Takeda Pharmaceuticals
- Wei Liu, Channing Laboratory, Harvard University
- Jennifer Lund, University of North Carolina, Chapel Hill
- Frank Xiaoqing Liu, Global Health Economics and Outcomes Research, Baxter Healthcare
- Jesus M Lopez Arrieta, Hospital de Cantoblanco
- Peggy Monica McKinnon Crompton, Health Economics and Outcomes Research, Cubist Pharmaceuticals
- Vinay Mehta, Pharmacoepidemiology, Merck
- Laura Menditto, US Health Outcomes, GlaxoSmithKline
- Sharon Meropol, Department of Epidemiology and Biostatistics, Case Western Reserve University School of Medicine
- Shannon Michels, Comprehensive Health Insights-A Humana Company
- Debbie Moritz, Epidemiology, Genentech
- Elaine Morrato, Health Systems, Management and Policy, University of Colorado at Denver
- Joaquin Mould, Health Econ. & Outcomes Res., Latin America & Primary Care Products, Pfizer
- Yuen Mi Yim, Biostatistics, Genentech
- Erwan Muros, Global Medical Science & Communication, Actelion Pharmaceuticals Ltd.
- Lakshmi Murthy, NICE
- Siva Narayanan, Medical Affairs, Human Genome Sciences, Inc.
- Winnie Nelson, Health Economics & Outcomes Research, Janssen Scientific Affairs, LLC
- Jude Nwokike, Management Sciences for Health
- Alexis Ogdie, Rheumatology Division, University of Pennsylvania
- William Olson, Research and Analysis Strategy, Janssen Scientific Affairs, LLC
- Niki Palmetto, Worldwide Safety Strategy, Pfizer
- Mary Panaccio, US Medical Affairs, Sanofi-Aventis
- Jongbae Jay Park, University of North Carolina at Chapel Hill
- Hannah Patrick, NICE
- Federica Pisa, Institute of Hygiene and Clinical Epidemiology, University Hospital of Udine, Italy
- Nicole Pratt, Quality Use of Medicines and Pharmacy Resarch Centre, University of South Australia
- Donald R. Miller, Epidemiology and Health Services Research, Boston University
- Diane Randall, CNS Operations, Bristol-Myers Squibb
- Cristina Rebordosa, Novartis
- Valencia Remple, Health Economics & Outcomes Research, Pfizer
- Evelyn Rodriguez, Bracco Diagnostics Inc.
- Karie Rosolowski, American Society of Plastic Surgeons
- Matthew Rousculp, Comparative Effectiveness Research, GlaxoSmithKline
- Shiva Sajjan, Merck
- Grannum Sant, Sanofi-Aventis
- Tania Schink, Prevention Research and Epidemiology, BIPS
- Amy P. Sing, Genomic Health
- Jim Slattery, Pharmacovigilance and Risk Management, European Medicines Agency
- Patricia Splett, Department of Food Science and Nutrition, University of Minnesota
- Paul Stang, Epidemiology, Johnson & Johnson Pharmaceutical Research and Development
- Julio E Vazquez Suarez, Eli Lilly, Puerto Rico
- Sarah T. Tonn, Clinical Quality and Performance Evaluation, American Academy of Neurology
- Iris Tam, Managed Care Medical Communications, Genentech
- Boxiong Tang, Outcomes Research, Pfizer Inc.
- Thang Tran, Health Economics & Outcomes Research, Pfizer
- Hanae Ueyama, Department of Pharmacoepidemiology, Kyoto University
- Luis Veloso, Eurotrials
- Patrice Verpillat, Global Market Access and Pricing Strategies, Sanofi-Aventis
- Naunihal S. Virdi, Medical Affairs, LifeScan
- Ute Weisgerber-Kriegl, Hoffmann-La Roche Ltd
- Grace West, Global Statistical Science, Amgen Inc.
- Chuntao Wu, Sanofi
- Seet Wymen, Clinical Research Centre, Ministry of Health, Malaysia
- Fei Xue, Amgen Inc.
- Yuer Yan, Global Patient Safety, Eli Lilly
- Yea-Huei Kao Yang, Institute of Clinical Pharmacy and Pharmaceutical Sciences, National Cheng Kung University, Taiwan
- Huiying Yang, Allergan
- Linda Yau, Biometrics & Health Outcomes and Payer Support, US Medical Affairs, Genentech
- Mellissa Yong, Global Epidemiology, Amgen, Inc.
- Marianne Yood, EpiSource
- Shengsheng Yu, Merck
- Jie Zhang, Health Economics and Outcomes Research, Novartis Pharmaceuticals Corp.
- Helga Zoega, Mt. Sinai Medical Center
Other Collaborators and Supporters have provided constructive comments
- José Luis Alloza, Dep. de Farmacología-Facultad de Medicina, The U. of Alcalá, Madrid, Spain
- G. Lawrence Atkins, Public Policy and Reimbursement, Schering-Plough
- Jesse Berlin, Pharmacoepidemiology, J&J Pharmaceutical R&D
- Michael N. Cook, Global Safety Surveillance & Epidemiology, Pfizer
- Christina Farup, Evidence Based Medicine, Novartis
- Dale Glasser, Consultant
- Richard Gliklich, President, Quintiles Outcome
- R.M.C. Herings, Dpt of Health Policy and Mgmt, Erasmus MC. Rotterdam, The Netherlands
- Ken Hornbuckle, Risk Management & Pharmacoepidemiology, Eli Lilly
- Mark V. Johnston, College of Health Sciences. University of Wisconsin
- Kristijan Kahler, HE&R, ABGU & NS Evidence Based Medicine, Novartis
- Stephen Motsko, Risk Management & Pharmacoepidemiology, Eli Lilly
- John Parkinson, Clinical Practice Research Datalink
- Jeff Schein, Scientific Affairs, Ortho-McNeil Janssen
- Hemal Shah, Health Economics & Outcomes Res., Boehringer Ingelheim Pharmaceuticals, Inc.
- J. Michael Sprafka, Amgen
- Til Stürmer, Dept. of Epidemiology, U. of North Carolina, School of Public Health, Chapel Hill
- Alexander M. Walker, Principal, Whiscon
- Douglas J. Watson, Medical/Scientific Liaison, Merck Research Laboratories
Supported by
